Conferences

Source: OncLive, July 2019 Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival (RFS) for patients with resectable advanced melanoma…

Source: OncLive, July 2019 Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and…

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the…

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the…